1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A77E53CE07EC85F70025897B0030087D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medicals-road-map-for-social-media-success-oncology
18
19
203.235.188.113
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Medical Affairs Excellence

Medical’s Road Map for Social Media Success in Oncology

ID: POP-359


Features:

11 Info Graphics

29 Data Graphics

310+ Metrics

3 Narratives


Pages: 48


Published: 2023


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Social media has created a new opportunity for Medical Affairs groups within Oncology companies to engage with health care providers, thought leaders, patients, digital opinion leaders, and other key stakeholders.

Best Practices, LLC conducted benchmarking research to build a roadmap for Medical Affairs’ social media success in Oncology. This report investigates current trends and success factors in harnessing social media for effectively educating the oncology market. It establishes benchmarks around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Manufacturing; Consumer Products; Diagnostic; Communications; Medical; Biopharmaceutical; Health Care; Consulting


Companies Profiled:
AbbVie; Avidity Biosciences; AstraZeneca; Baxter Healthcare; Bayer; BIAL; Boehringer Ingelheim; Boston Scientific; Complete HealthVizion | An IPG Health Company; Dompé; DURECT Corporation; Eisai; Elevation Oncology; EMD Serono; Ethicon Endo-Surgery Inc.; Gossamer Bio; Grifols; Hoya Vision Care; Janssen; LEO Pharma; MedVal Scientific Information Services; Merck KGaA; Merck Sharp & Dohme; Merz Pharma; Merz Aesthetics; Myovant Sciences; Nobel Biocare; Novartis; Novartis Oncology; Novo Nordisk; PRECISIONscientia; Servier; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

Study Snapshot

Best Practices, LLC engaged 48 Medical leaders from 36 biopharma companies in this benchmarking research using an integrated framework to examine current trends and future directions to construct the roadmap for social media success in Oncology under Medical Affairs auspices. For therapeutic area-specific insights, two specific segments were investigated in this study: Responses from 19 social media leaders at 14 Oncology organizations were analyzed against the rest of the total benchmark class.

Key topics covered in this report include:

  • Social Media Structure and Management in Oncology
  • Social Media Activities
  • Social Media Omnichannel Integration in Oncology
  • Social Media Message Characteristics and Performance Measurement
  • Social Media Innovation in Medical
  • Social Media Content and Sharing Trends in Oncology

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Social Media Accounts: The consensus is that multiple avenues of outreach are most effective: The social scorecard shows multiple accounts maintained by 84% of Oncology segment and 68% of rest of the benchmark class.

  • Resharing Social Info: Most medical groups prohibit info resharing from other parties; however, Oncology is far more proactive – with over half of the teams regularly re-sharing other’s content on social media.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Section 1: Executive SummaryPg. 3-14
II.
Section 2: Social Media StructurePg. 15-22
III.
Section 3: Social Media ActivitiesPg. 23-34
IV.
Section 4: Social Media Omnichannel IntegrationPg. 35-41
V.
Section 5: Social Media Message Characteristics and Performance MeasurementPg. 42-47
VI.
About Best Practices, LLCPg. 48

    List of Charts & Exhibits

    I. Social Media Structure

    • Geographic span of responsibility of Oncology organizations
    • Social media account quantity of organizations – Oncology segment vs. Rest of the benchmark class
    • Range of multiple social media accounts
    • Separation of social media accounts – Oncology segment vs. Rest of the benchmark class
    • Involvement of Medical Affairs in social media initiatives – Oncology segment vs. Rest of the benchmark class
    • Share of social media account ownership
    • Medical Affairs’ vendor utilization for social media activities – Oncology segment vs. Rest of the benchmark class

    II. Social Media Activities

    • Most utilized social media platforms by Medical Affairs groups – Oncology segment vs. Rest of the benchmark class
    • Target audiences for Medical’s social media activities – Oncology segment vs. Rest of the benchmark class
    • Goals for Medical Affairs group’s social media efforts – Oncology segment vs. Rest of the benchmark class
    • Proactive vs. reactive social media interactions over time
    • Proactive social media activities for Medical – Oncology segment vs. Rest of the benchmark class
    • Effectiveness of social media platforms for conveying therapeutic/disease state information, on-label clinical study data, and clinical study data for a new or expanded indication
    • Effectiveness of social media platforms for posting information on new scientific papers/abstracts, sharing posts from KOLs/DOLs/thought leaders, and sharing industry commentary
    • Effectiveness of social media platforms for sharing commentary from groups such as patient advocacy groups
    • Effectiveness of conveying therapeutic/disease state information, on-label clinical study data, and clinical study data for a new or expanded indication in engaging each target audience
    • Effectiveness of posting information on new scientific papers/abstracts, sharing posts from KOLs/DOLs/thought leaders, and sharing industry commentary in engaging each target audience
    • Effectiveness of commentary from community groups in engaging each target audience

    III. Social Media Omnichannel Integration

    • Platforms on which Medical conducts omnichannel activities for social media
    • Medical group’s strategy for handling misleading or non-compliant information on social media
    • Medical’s content re-sharing policies on social media – Oncology segment vs. Rest of the benchmark class
    • Types of content re-shared from other (unaffiliated) accounts by Medical Affairs
    • Organizational structure used by Medical Affairs to engage in omnichannel activities

    IV. Social Media Message Characteristics and Performance Measurement

    • Presence of committees for specifically reviewing social media content from a Medical compliance lens – Oncology segment vs. Rest of the benchmark class
    • Percentage of brand-oriented, molecule-oriented, and disease state-oriented social media posts
    • Percentage of Medical Affairs group’s social media posts which are primarily graphic, contain a mix of both graphics and text, and are primarily text – Oncology segment vs. Rest of the benchmark class
    • Effectiveness of each key performance indicator for measuring the success of Medical Affairs group’s social media engagements – Oncology segment vs. Rest of the benchmark class
    • External stakeholders that contribute to the development of content for Medical Affairs group’s collaborative social media activities – Oncology segment vs. Rest of the benchmark class